Based on this understanding, IgG1 monoclonal antibodies that directly target various forms A plaques have been developed, resulting in drugs such as Aducanumab (marketed as Aduhelm) that has been approved for use by the FDA (Dhillon, 2021)
By inhibiting the NNMT enzyme, it prevents the excessive consumption of NAD+, a critical molecule that your cells need for energy production, DNA repair, and maintaining healthy metabolic function
While not a standalone solution, it complements diet and exercise by boosting energy and metabolic function
This comparison helps people who want to understand the difference between oral and injectable peptide therapy before speaking with a provider
Expected timeline: Days 1-3: Continued acute symptoms, peptide beginning to accumulate Days 4-7: Inflammation reduction often noticeable, pain decreasing Week 2-3: Significant improvement in most acute strains Week 4-6: Return to normal function, consider tapering Complementary approaches: Gentle movement, avoiding complete rest
:max_bytes(150000):strip_icc()/rs-the-ordinary-copper-peptides-serum-tout-caf2cd9e207649e7bdcd8c0a68890047.jpg)
